Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAndre De Menezes Silva CorraesPKPrashant KapoorCTCarlyn Rose Tan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows poor prognosis with median overall survival of 5.7 months in relapsed myeloma after immunotherapy.

Key Points

  • To assess clinical outcomes of patients treated with BCMA- and GPRC5D-targeted therapies in relapsed myeloma.
  • Conducted a retrospective multi-center study of RRMM patients treated with BCMA- and GPRC5D-targeted treatments.
  • Analyzed outcomes including progression-free survival (PFS1) and overall survival (OS).
  • Utilized Kaplan-Meier estimates and event-free probabilities.
  • Included 49 patients who had undergone dual-targeted therapies.
  • Median PFS during the last dual exposure was approximately 4 months.
  • Median OS from progression was about 5.7 months, indicating a poor prognosis.

Cite This Study

Corraes et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9ddhttps://doi.org/10.1182/blood-2025-4598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  2. 2Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States2025 · 4 citations
  3. 3Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  4. 4Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025